Cero Therapeutics Reports $1.03 Million Net Loss, Advances CER-1236 in Clinical Trials

Cero Therapeutics Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $1.03 million for the quarter, a substantial decrease from the $5.42 million loss reported in the same period last year, marking an 81% improvement. Total operating expenses for the quarter were $3.85 million, down 18.6% from $4.72 million in the prior year, primarily due to reduced research and development costs, which fell by 37% to $1.74 million. General and administrative expenses increased slightly by 7.1% to $2.11 million.

In terms of liquidity, Cero Therapeutics ended the quarter with approximately $937,512 in cash and cash equivalents, a significant decline from $1.66 million at the end of the previous fiscal year. The company reported a working capital deficit of $30.9 million and an accumulated deficit of $97.8 million. During the first half of 2026, the company utilized about $5.1 million in cash for operating activities, while also raising $4.36 million through financing activities, including proceeds from the sale of common stock and convertible notes.

Strategically, Cero Therapeutics is advancing its lead product candidate, CER-1236, which is currently in a Phase 1/1b clinical trial for acute myeloid leukemia (AML). The company received FDA clearance for its Investigational New Drug application in November 2024 and has since dosed multiple patients in the trial. The company is also pursuing additional indications for CER-1236, including non-small cell lung cancer and ovarian cancer, with an Investigational New Drug application accepted by the FDA in March 2025.

Operationally, Cero Therapeutics has faced challenges, including a delisting from Nasdaq in October 2025, leading to its shares trading on the OTCQB market. The company has also undergone significant changes in its capital structure, including the reclassification of certain preferred stock as liabilities due to insufficient authorized shares to cover potential conversions. As of June 30, 2026, the company had approximately 1.78 billion shares of common stock potentially issuable upon conversion of preferred stock and warrants, highlighting the potential dilution for existing shareholders.

Looking ahead, Cero Therapeutics acknowledges the need for additional funding to support its ongoing research and development activities. The company has expressed uncertainty regarding its ability to secure sufficient capital, which could impact its operational plans and timelines for product development. The management's focus remains on advancing clinical trials and seeking regulatory approvals while navigating the financial challenges posed by its current cash position and market conditions.